Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
67 recruiting
Showing 1–20 of 67 trials
Recruiting
Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled12 locationsNCT07222267
Recruiting
Phase 3
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Renal Cell CarcinomaNeoadjuvant
ZHOU FANGJIAN298 enrolled8 locationsNCT05738694
Recruiting
Phase 3
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Akeso416 enrolled1 locationNCT06767527
Recruiting
Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1Phase 2
Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer
Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.105 enrolled30 locationsNCT07367516
Recruiting
Phase 1Phase 2
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Akeso280 enrolled2 locationsNCT06530251
Recruiting
Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 1
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Advanced Solid TumorMalignant MesotheliomaMetastatic Malignant Solid Tumor
InSilico Medicine Hong Kong Limited100 enrolled10 locationsNCT06566079
Recruiting
Phase 1Phase 2
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.42 enrolled1 locationNCT07208149
Recruiting
Not Applicable
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
Oral Tongue Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University190 enrolled28 locationsNCT07402525
Recruiting
Phase 1Phase 2
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Early Phase 1
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer Castration-resistant Prostate Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10 enrolled1 locationNCT07156045
Recruiting
Early Phase 1
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer Castration-resistant Prostate Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences15 enrolled1 locationNCT07298239
Recruiting
Phase 1
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled1 locationNCT06609187
Recruiting
Phase 1Phase 2
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer(TNBC)+2 more
Jacobio Pharmaceuticals Co., Ltd.102 enrolled8 locationsNCT05490472
Recruiting
Phase 2
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University116 enrolled7 locationsNCT07248956